BTG2 is a member of the BTG/Tob protein family with anti-proliferative characteristics. It is involved in various cellular processes such as cell-cycle progression, differentiation or apoptosis, cell growth, and survival. It contains a conserved BTG (or APRO) domain in the N-terminal end.
Synonyms: Anti-BTG2 protein antibody produced in rabbit; Anti-NGF-inducible anti-proliferative protein PC3 antibody produced in rabbit
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: BTG2 has high impact on the DNA-damage-induced G2/M cell-cycle arrest. Its activity is regulated by p53. It acts as a coactivator and corepressor of estrogen receptor ERa in vitro. It modulates the transcription regulation mediated by ERa. It is a primary response genes induced by growth factors and tumour promoters. It interacts with Pop2 (pyrin-only protein 2)/Caf1 (CCR4-associated factor 1), active Pop2/Caf1 and Ccr4 deadenylases during mRNA decay control.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC